欧姆龙医疗捐赠4000台血压计，并通过基于人工智能的Intellisense AFib技术推进房颤筛查-动脉网

OMRON Healthcare Donates 4,000 Blood Pressure Monitors and Advances AFib Screening with AI-based Intellisense AFib Technology

CISION 等信源发布 2025-04-24 16:00



可切换为仅中文







- Intellisense AFib Technology Able to Detect Possible Atrial Fibrillation with Every Measurement; May

- Intellisense AFib技术能够通过每次测量检测可能的心房颤动；可能

17 Marks

17分

World Hypertension Day during May Measurement Month -

五月测量月期间的世界高血压日 -

KYOTO, Japan

日本京都

，

April 24, 2025

2025年4月24日

/PRNewswire/ -- OMRON Healthcare Co., Ltd. (Head Office: Muko,

/PRNewswire/ -- 欧姆龙健康医疗株式会社（总部： Muko，

Kyoto Prefecture

京都府

; hereinafter referred to as 'the Company') is proud to continue its long-term commitment to the sponsorship of May Measurement Month (MMM), an awareness-raising campaign of blood pressure monitoring. As part of this commitment, the Company will donate approximately 4,000 blood pressure monitors to MMM.

；以下简称“公司”）自豪地继续其对五月血压测量月（MMM）活动的长期赞助承诺，这是一项提高血压监测意识的活动。作为此项承诺的一部分，公司将向MMM捐赠大约4000台血压计。

This year, the donated devices include blood pressure monitors that detect possible atrial fibrillation (AFib) using the new AI-based Intellisense AFib technology, as well as blood pressure monitors featuring integrated ECG technology..

今年，捐赠的设备包括使用基于人工智能的新Intellisense AFib技术检测可能的心房颤动（AFib）的血压计，以及具有集成心电图技术的血压计。

Logo:

标志：

https://kyodonewsprwire.jp/img/202504177579-O1-SWNJGnOc

OMRON Healthcare has partnered with MMM since 2017 to promote and help to create awareness of the dangers of raised blood pressure and hypertension and to date has donated approximately 30,000 blood pressure monitors across 100 countries. Now, in its seventh year running, this initiative has been crucial in educating hypertensive patients to measure their blood pressure and to support early detection of AFib to help reduce stroke risk..

欧姆龙健康医疗自2017年起与MMM合作，宣传和帮助提高人们对高血压和血压升高危险的认识，迄今为止已向100个国家捐赠了约30,000台血压计。如今，这项倡议已进入第七个年头，在教育高血压患者测量血压和支持早期发现房颤以帮助降低中风风险方面发挥了关键作用。

'Atrial fibrillation is a potentially life-threatening arrhythmia, and people with high blood pressure are at significantly greater risk of developing it. Regular monitoring of blood pressure is a crucial tool in identifying those risks and enables people to manage hypertension more effectively. With the donation of these monitors, we are able to support earlier detection, better treatment and, ultimately, save more lives,' said Professor Neil R Poulter, Chief Investigator and Chair of Trustees, of May Measurement Month..

“心房颤动是一种可能危及生命的 arrhythmia，高血压患者发生心房颤动的风险显著增加。定期监测血压是识别这些风险的关键工具，有助于人们更有效地管理高血压。通过捐赠这些血压计，我们能够支持更早的检测、更好的治疗，并最终挽救更多生命，”May Measurement Month 的首席研究员兼理事会主席尼尔·R·普尔特教授表示。

According to the World Health Organization (WHO), high blood pressure is responsible for more than 10 million deaths worldwide each year. And alarmingly, approximately 1 in 4 people with AFib are initially asymptomatic.*1 If left untreated, hypertension increases the risk of developing life-threatening cerebrovascular and cardiovascular diseases such as stroke and heart failure.

根据世界卫生组织 (WHO) 的数据，高血压每年在全球范围内导致超过 1000 万人死亡。令人担忧的是，大约四分之一的心房颤动 (AFib) 患者最初无症状。*1 如果不加以治疗，高血压会增加患上危及生命的心脑血管疾病（如中风和心力衰竭）的风险。

Early detection and proper treatment of hypertension can prevent serious complications. Home blood pressure monitoring is associated with better blood pressure control and therefore enhances prevention..

早期发现并正确治疗高血压可以预防严重并发症。家庭血压监测与更好的血压控制相关，因此有助于预防。

This year's MMM will be held from

今年的MMM将从以下日期举行：

May 1 to July 31

5月1日至7月31日

. The event will offer hands-on blood pressure measurements and provide advice on diet and blood pressure management. Additionally, visitors, in some regions, will be able to assess their AFib risk through blood pressure measurements and ECG recordings. Studies have confirmed that the incidence of AFib is about three times higher in hypertensive patients than in those with normal blood pressure*2.

活动将提供血压测量实践，并就饮食和血压管理提供建议。此外，在一些地区，参观者将能够通过血压测量和心电图记录来评估自己的房颤风险。研究已经证实，高血压患者的房颤发病率约为正常血压人群的三倍*2。

By donating blood pressure monitors that can detect the possibility of AFib to MMM, the Company is providing an opportunity to raise awareness of its risks among hypertensive patients..

通过向MMM捐赠可以检测房颤可能性的血压监测仪，该公司正在提供一个提高高血压患者对其风险认识的机会。

For more information about MMM, please visit:

有关 MMM 的更多信息，请访问：

www.maymeasure.org

。

*1 Gibbs H, et al; Clinical Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation Presentations in GARFIELD-AF: Implications for AF Screening. Am J Med. 2021 Jul;134(7):893-901.e11.

*1 Gibbs H, 等；GARFIELD-AF 中无症状和有症状心房颤动的表现的临床结果：对心房颤动筛查的意义。《美国医学杂志》2021年7月；134(7):893-901.e11。

*2 Senoo K, Yukawa A, Ohkura T, et al. Screening for untreated atrial fibrillation in the elderly population: A community-based study. Pizzi C, ed. PLoS ONE.2022;17(6):e0269506.

*2 千野 K，雪川 A，大仓 T，等。老年人群中未治疗心房颤动的筛查：一项基于社区的研究。Pizzi C编辑。PLoS ONE。2022；17（6）：e0269506。

About OMRON Healthcare

关于欧姆龙医疗

Committed to advance health and empower people worldwide to live life to the fullest, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment. Aiming to realize its vision 'Going for Zero, Preventive Care for the Health of Society,' the Company develops products and services for cardiovascular condition management, remote patient monitoring, respiratory care, and pain therapy devices.

致力于促进健康并赋予全世界人们充分享受生活的能力，欧姆龙健康医疗是临床验证过的创新家用健康监测和治疗医疗设备领域的全球领导者。为实现其“追求零疾病，为社会健康提供预防性护理”的愿景，公司开发了用于心血管状况管理、远程患者监护、呼吸护理和疼痛治疗设备的产品和服务。

These help healthcare professionals and patients to reduce cerebro-cardiovascular events, aggravation of respiratory diseases and restrictions due to chronic pain..

这些帮助医疗卫生专业人士和患者减少心脑血管事件、呼吸系统疾病的恶化以及慢性疼痛导致的限制。

With well over 350 million units sold globally*, OMRON provides the world's most recommended blood pressure monitors by healthcare professionals**. Throughout its history, OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat, and manage their medical conditions, and provides products and services in over 130 countries***..

在全球范围内销量超过3.5亿台*，欧姆龙提供的血压计被医疗保健专业人士**推荐为全球首选。在其发展历程中，欧姆龙健康一直致力于通过开发创新技术改善人们的生活，并为社会的可持续发展做出贡献，这些技术帮助人们预防、治疗和管理健康问题，同时其产品和服务覆盖了130多个国家***。

OMRON Healthcare Group is headquartered in

欧姆龙健康医疗集团总部位于

Kyoto, Japan

京都，日本

。

* Cumulative sales of home-use digital blood pressure monitors worldwide. (as of

* 全球家用数字血压计的累计销售额。（截至

May 2023

2023年5月

)

** 1 Frost & Sullivan Survey, Blood pressure clinician perception tracker surveys.